High intensity focused ultrasound (HIFU) for pancreatic carcinoma: evaluation of feasibility, reduction of tumour volume and pain intensity
AbstractObjectivesPrognosis of patients with locally advanced pancreatic adenocarcinoma is extremely poor. They often suffer from cancer related pain reducing their quality of life. This prospective observational study aimed to evaluate feasibility, local tumour response, and changes in quality of life and symptoms in Caucasian patients with locally advanced pancreatic cancer treated by ultrasound guided high intensity focused ultrasound (HIFU).MethodsThirteen patients underwent HIFU, five with stage III, eight with stage IV UICC disease. Ten patients received simultaneous palliative chemotherapy. Postinterventional clinical assessment included evaluation of quality of life and symptom changes using standardized questionnaires. CT and MRI follow up evaluated the local tumour response.ResultsHIFU was successfully performed in all patients. Average tumour reduction was 34.2 at 6 weeks and 63.9 at 3 months. Complete or partial relief of cancer related pain was achieved in 10 patients (77 five of whom required less analgesics for pain control. Quality of life was improved revealing increased global health status and alleviated symptoms. HIFU treatment was well tolerated. Eight patients experienced transient abdominal pain directly after HIFU.ConclusionsHIFU ablation of pancreatic carcinoma is a feasible, safe and effective treatment with a crucial benefit in terms of reduction of tumour volume and pain intensity.Key Points* US guided HIFU is feasible and safe for patients with unresectable pancreatic cancer. HIFU can considerably reduce tumour volume and cancer related pain. Patients treated with HIFU experienced significant and lasting reduction of pain intensity. HIFU has a crucial clinical benefit for patients with pancreatic cancer.
European Radiology